FDA to review broader access to restricted peptides in July The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and You may have seen headlines recently claiming peptides like MOTS C or BPC 157 are back let's talk about what this means. In 2023, the FDA placed 19 commonly used peptides into Category Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law